Brca2 Deficiency Does Not Impair Mammary Epithelium Development but Promotes Mammary Adenocarcinoma Formation in p53+/− Mutant Mice

Alison M. Y. Cheung,1,2 Andrew Elia,1 Ming-Sound Tsao,2 Susan Done,2 Kay-Uwe Wagner,3 Lothar Hennighausen,4 Razgallah Hakem,1,2 and Tak W. Mak1,2

1Advanced Medical Discovery Institute, Toronto, Ontario, Canada; 2Ontario Cancer Institute and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; 3Epiphel Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska; and 4Laboratory of Genetics and Physiology, National Institute of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, Maryland

ABSTRACT

Brca2 is an important tumor suppressor associated with susceptibility to breast cancer. Although increasing evidence indicates that the primary function of Brca2 is to facilitate the repair of DNA damage via the homologous recombination pathway, how Brca2 prevents breast cancer is largely unknown. To study the role of Brca2 specifically in mammary epithelial development, we crossed mice bearing the conditionally deficient allele Brca2<sub>fl9–10</sub> to mouse mammary tumor virus- or whey acidic protein-Cre transgenic lines. Analysis of these animals showed that Brca2 is not required for epithelial expansion in mammary glands of pregnant mice. In addition, examination of mammary gland involution revealed normal kinetics of mammary alveolar cell apoptosis after weaning of litters. Nevertheless, Brca2-deficient mice developed mammary adenocarcinomas after a long latency (average, 1.6 years). Detailed histopathological analysis of four of these tumors demonstrated that three of them showed abnormal p53 protein expression. A mutation in the p53 gene was detected in one case. Moreover, homozygosity versus heterozygosity for the Brca2 mutation skewed the tumor spectrum toward mammary adenocarcinoma development in p53+/− mice. Our data indicate that Brca2 is not essential for mammary epithelium development but that Brca2 deficiency and down-regulated p53 expression can work jointly to promote mammary tumorigenesis.

INTRODUCTION

The identification and cloning of the breast cancer susceptibility genes <i>BRCA1</i> and <i>BRCA2</i> genes has revealed the molecular basis of the majority of hereditary breast cancers in women (1, 2). Although the two <i>BRCA</i> genes are not homologous in sequence, they have similar expression patterns during cell cycle progression and in embryonic (3) and adult (1, 4, 5) tissues. Numerous biochemical studies of the human BRCA proteins have shown that both gene products are regulators of cellular genomic stability. Whereas BRCA1 has additional functions in transcription regulation, the control of centrosome number, and ubiquitination (for a recent review, see Ref. (6), the major identified function of BRCA2 is to bind to Rad51 and regulate the activity of this molecule during homology-directed recombination repair of DNA double-strand breaks (7). On one hand, the BRC repeats of BRCA2 (which mimic the oligomerization domain of Rad51 in structure) bind to Rad51 (8) and prevent it from binding to single-stranded DNA to form nucleoprotein complexes. Rad51-mediated DNA repair activity is thus inhibited (9). On the other hand, a different region near the COOH terminus of BRCA2 binds single-stranded DNA and stimulates Rad51-mediated recombination in vitro (10). In addition, it was recently shown that the portion of the BRCA2 protein encoded by exon 3 binds to a novel protein called EMSY, an interaction that leads to the silencing of BRCA2-mediated transcriptional activation (11). Animal studies have also supported a role for BRCA2 in controlling genomic stability. Murine cells, which completely lack Brca2 or express a truncated form of Brca2, have a proliferative defect characterized by increased expression of the tumor suppressor gene p53 and its transcriptional target p21<sup>WAF1/Cip1</sup>. Brca2-deficient cells are also more sensitive to apoptosis induced by DNA-damaging agents (12–15).

Although the biochemical function of BRCA2 is now known, how it acts as a tumor suppressor in human breast and ovarian cancers is still a mystery. Mutations in BRCA2 contribute to 32% of hereditary breast cancers in women and to 14% in men (16). In mice, mammary epithelium that lacks Brca2 expression undergoes cancerous transformation after a long latency (17), and tumor cells in this tissue exhibit genomic instability. Furthermore, simultaneous loss of Brca2 and p53 in epithelial tissues drastically increases the incidence of skin and mammary tumors (18). However, the involvement of Brca2 in normal mammary epithelium development has not been investigated. Morphogenesis of the mammary gland occurs in several stages, starting with a fetal anlage, which undergoes ductal elongation and branching (19). During puberty, the ductal tree undergoes additional branching to expand throughout the fat pad. However, maximal expansion and proliferation of the ductal and alveolar epiteliah to generate a fully functional mammary gland with secretory lobulo-alveolar structures does not occur until pregnancy. After weaning, the mammary gland involutes via massive apoptosis of epithelial cells that returns the gland to its prepregnant-like state. These processes are stringently regulated by steroid and peptide hormones (20). Expression studies have demonstrated that BRCA2 is up-regulated in response to the steroid and growth hormones (20). Expression studies have demonstrated that BRCA2 is up-regulated in response to the steroid and growth hormones (20). Furthermore, simultaneous loss of Brca2 and p53 in epithelial tissues drastically increases the incidence of skin and mammary tumors (18). However, the involvement of Brca2 in normal mammary epithelium development remains to be defined, as does the potential role of this protein in mammary cell proliferation during pregnancy and/or apoptosis during involution.

To address these questions, we took advantage of previously generated Brca2<sub>fl9–10</sub> mice in which Brca2 exons 9–10 are floxed (flanked by loxP; Ref. 21). We crossed Brca2<sub>fl9–10</sub> mice with MMTV-Cre or WAP-Cre transgenic mice to produce mutants that specifically lack Brca2 at different stages of mammary gland development. In WAP-Cre transgenic mice, Cre recombinase is induced only during late pregnancy and lactation (22, 23). In MMTV-Cre transgenic mice, the mouse mammary tumor virus (MMTV) long terminal repeat promoter drives the expression of Cre recombinase in mammary epithelium (among other tissues) before puberty (22, 23). The generation of these mutant animals allowed us to examine the effect of Brca2 deficiency at critical points of mammary gland development and tumorigenesis.

MATERIALS AND METHODS

Generation of Mammary Gland-Specific Brca2-Deficient Mice. The generation of mice bearing a floxed allele of Brca2 exons 9–10 (Brca2<sub>9–10</sub>) has been described previously (21). To inactivate Brca2 specifically in mammary epithelium, Brca2<sub>9–10</sub> mice were crossed to MMTV-Cre transgenic mice (22) expressing Cre recombinase under the control of MMTV long
terminal repeat promoter or to WAP-Cre transgenic mice (22) expressing Cre recombinase under the control of the whey acidic protein (WAP) promoter. The resulting mutant mice (Brca2fl9; WAP-Cre and Brca2fl9–10; WAP-Cre) were analyzed in both 129/C57BL/6 and FVB/C57BL/6 genetic backgrounds. Mammary glands collected from a total of 68 129/C57BL/6 and 20 FVB/C57BL/6 mice of various Brca2 andCre genotypes were used for whole mount, histological, terminal deoxynucleotidyl transferase-mediated nick end labeling, and Southern and Western analyses as described below. No phenotypic differences were observed between genetic backgrounds. For timed pregnancies, male and female mice were mated overnight, and females were scored for vaginal plagues the next morning. The presence of vaginal plagues was taken to represent pregnancy day0.5. Brca2fl9–10; WAP-Cre and Brca2fl9–10; WAP-Cre mice were also crossed to p53+/− mice (Taconic) to produce Brca2fl9–10; MMTV-Cre; p53+/− and Brca2fl9–10; WAP-Cre; p53+/− mice. All experiments were performed in compliance with the guidelines of the Ontario Cancer Institute Animal Care Committee.

**Induction of Involution and Mammary Tissue Collection.** Litter size was kept at 5 pups to equalize suckling frequency on each teat and to minimize variation between mice. To induce involution, pups were removed at day 10 after birth (d10L). Day 1 of involution (d1i) began 24 h after pup removal, with all subsequent days being designated accordingly. For mammary tissue collection, one of the abdominal mammary glands was fixed in 10% buffered formalin (Fisher Scientific, Nepean, Ontario, Canada), whereas the other was saved for whole mount analysis (see below). The first or second thoracic mammary glands were collected and a portion of the tissue was digested in tissue lysis buffer (10 mm Tris, 1 mm EDTA, 0.1 mm NaCl, 1% SDS, and 0.2 mg/ml proteinase K) and subjected to phenol/chloroform extraction to obtain genomic DNA from mammary tissues and performed Southern blotting using a previously described probe for p53 (21). Levels of recom- bination of the floxed allele between heterozygous and homozygous Brca2fl9–10 mice, we performed densitometric quantitation of the pixel intensities of the restriction fragment bands within the rectangles indicated in Fig. 1A–C. We then calculated the percentage of total floxed alleles that had recombined: [volume of the recombined (Δ9–10)/volume of (recombined + nonrecombined)(9–10) or WT allele] × 100%. We observed a low level of recombination (9.99%) in cells from the mammary glands of d16.5 pregnant Brca2fl9–10; WAP-Cre mice, which was nevertheless double the level of recombination observed in Brca2fl9–10; WAP-Cre females at the same stage of pregnancy (4.48%; Fig. 1A). Because the genomic DNA had been collected from whole fat pads, this modest level of recombination may reflect the relatively low number of epithelial cells present in this tissue. A higher level of recombination (20.86%) was observed in Brca2fl9–10; WAP-Cre mice by several hours postpartum (Fig. 1B), consistent with the normal activation of the WAP promoter during late pregnancy and lactation (22). This level of recombination is consistent with that observed for mice with a mammary epithelium-specific mutation of Brca1 (Brca1 KO/–; WAP-Cre mice; Ref. 25). By day 21 postweaning, 25.10% of cells in the mammary tissue of Brca2fl9–10; WAP-Cre mice showed recom- bination of the floxed allele (Fig. 1C), suggesting that Brca2-deficient
epithelial cells can survive after involution despite the ensuing massive apoptosis of lobulo-alveolar cells.

We also investigated levels of recombination of the floxed allele in the mammary tissue of Brca2fl9–/− to −/−, MMTV-Cre mice using Southern blotting and PCR (Fig. 1, D–E). Recombination of the Brca2fl9–/− allele in cells of virgin mammary tissue of these animals was almost undetectable using Southern blotting (Fig. 1D). To investigate whether recombination could be detected using PCR, we carried out amplifications using primers that bound to either the intron between exons 7 and 8 or the intron between the LoxP site and exon 11. A product of size 450 bp was expected if exons 9 and 10 were successfully removed from the floxed Brca2 allele. As shown in Fig. 1E, the recombined Brca2fl9–/− allele was detected in all tissues examined in 2 Brca2fl9–/−; MMTV-Cre mice (Fig. 1E, Lanes 1 and 3). These data indicate that a low but detectable level of recombination of the Brca2fl9–/− allele gives rise to at least a few Brca2-deficient cells in the mammary tissue of Brca2fl9–/−; MMTV-Cre mice. The observation that Brca2 recombination had also occurred in a number of other tissues is in agreement with the previously reported leakiness of this transgenic line (23).

Normal Ductal and Alveolar Epithelium Proliferation in Pregnant Brca2fl9–/−; MMTV-Cre Mice. Brca2fl9−/−/Wap-Cre mice show a defect in mammary ductal tree expansion during pregnancy that is accompanied by increased apoptosis, suggesting that WT Brca1 is required for normal mammary cell proliferation and ductal tree morphogenesis (25). Embryonic cells from mice with a homozygous truncation mutation of Brca2 also demonstrate a block in proliferation in association with enhanced expression of p53 and p21 proteins (12). To determine whether Brca2 is required for the proliferation of mammary epithelial cells, we examined whole mount preparations of mammary glands from pregnant Brca2fl9–/−; MMTV-Cre and control mice (Fig. 2). Expansion of the ductal and alveolar epithelium during pregnancy depends on the signaling of both peptide and steroid sex hormones. Day 16 pregnant Brca2fl9–/−; MMTV-Cre mice were just as competent as heterozygous controls at expanding the ductal trees and forming lobulo-alveolar structures, suggesting that Brca2 is not required for mammary epithelial cell proliferation (Fig. 2, A and B). We also examined the mammary ductal trees from mutant and control mice at several hours postpartum (Fig. 2, C and D). Again, the proliferation of Brca2-deficient epithelial cells appeared to be normal. A similar study using mammary tissue from Brca2fl9–/−; MMTV-Cre mutant mice also showed normal proliferation at day 16 of pregnancy and postpartum (data not shown).

Brca2-Deficient Mammary Epithelial Cells Demonstrate Normal Kinetics of Apoptosis during Involution. Embryonic cells from Brca2-null or Brca2 truncation mutant mice demonstrate increased sensitivity to DNA-damaging stress (12, 13). Similarly, activated T lymphocytes from mice with a T-cell-specific mutation of Brca2 (Brca2fl9–/−; Lck-Cre mice) exhibit an elevated level of spontaneous cell death (21). These observations can probably be attributed to the involvement of Brca2 in the regulation of DNA damage repair. DNA
aberrations accumulate in cells proliferating in the absence of Brca2, which in turn activates the apoptotic machinery. To determine whether proliferating Brca2-deficient mammary epithelial cells were also sensitized to apoptosis, we studied involution in Brca2<sup>10−/−</sup>; WAP-Cre<sup>+/−</sup> and control Brca2<sup>10−/−</sup>; WAP-Cre mice (Fig. 3). Analysis of H&E-stained sections from control mammary glands obtained at various days after forced weaning of pups revealed morphological changes that started as early as the first day of involution (d1i; Fig. 3A). Epithelial cells lining the milk-containing alveoli of control mice started to be shed into the lumens, a trend more noticeable by day2i. By day 3 of involution, the alveoli had almost completely collapsed and adipose tissue had begun to reconstitute the fat pad. This process continued until day7i when the gland completed its regression and returned to the prepregnant-like state. Notably, the morphological changes in Brca2<sup>10−/−</sup>; WAP-Cre mammary tissue were indistinguishable in pattern and kinetics from those of the Brca2<sup>10−/−</sup>; WAP-Cre controls. We then quantified the level of apoptosis by terminal deoxynucleotidyl transferase-mediated nick end labeling assay. Comparable levels of terminal deoxynucleotidyl transferase-mediated nick end labeling-positive cells were detected at d1i, d2i, and d3i in the involuting mammary glands of both mutant and control mice (Fig. 3B), suggesting that Brca2 deficiency does not affect apoptosis in mouse mammary glands. This conclusion was additionally confirmed by analysis of activated caspase-3 in whole cell lysates prepared from involuting glands (Fig. 3C). Activated caspase-3 was not detectable before day 3 of involution (data not shown), consistent with a previous study (26). Analyses of several samples from d3i and d4i Brca2<sup>10−/−/+</sup>; WAP-Cre and Brca2<sup>10−/−</sup>; WAP-Cre mammary tissues demonstrated considerable variation but no reproducible differences in levels of cleaved caspase-3.

### p53 Status in Spontaneous Mammary Adenocarcinomas of Brca2-Deficient Mice.

Despite the normal development of mammary tissue in Brca2-deficient mice, 4 of 6 Brca2<sup>10−/−</sup>; MMTV-Cre female mice developed spontaneous mammary adenocarcinomas after a long latency (average 1.6 years; Table 1). Pathological evaluation was done according to the guidelines in the consensus report from the Annapolis meeting on the mammary pathology of genetically engineered mice (27). This latency period is comparable with the latency of 1.4 years previously reported for mammary adenocarcinoma development in Brca2<sup>10−/−</sup>; Wap<sup>cre/cre</sup> mice (17). Southern blotting indicated that the recombination of both Brca2<sup>10−/−</sup> alleles occurred in almost all tumor cells, suggesting that mutation of Brca2 is responsible for the cancerous transformation of mammary cells (Fig. 4A). These data also suggest that, although there were few cells in the mammary tissue of Brca2<sup>10−/−</sup>; MMTV-Cre mice with a deletion of Brca2 exons 9 and 10, these cells were sufficient to initiate tumorigenesis.

Several lines of evidence have indicated that p53 signaling is often abrogated in human BRCA-associated breast cancers (28). In a mouse model, simultaneous loss of Brca2 and p53 in the epithelium acted synergistically to accelerate the development of breast

<table>
<thead>
<tr>
<th>Mouse</th>
<th>Tumor type</th>
<th>Age (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mammary adenocarcinoma</td>
<td>384</td>
</tr>
<tr>
<td>2</td>
<td>Hemangiosarcoma (near hind limb)</td>
<td>475</td>
</tr>
<tr>
<td>3</td>
<td>Mammary adenocarcinoma</td>
<td>558</td>
</tr>
<tr>
<td>4</td>
<td>Mammary adenocarcinoma</td>
<td>608</td>
</tr>
<tr>
<td>5</td>
<td>Mammary adenocarcinoma</td>
<td>763</td>
</tr>
<tr>
<td>6</td>
<td>Stromal/sex cord tumor of the ovary</td>
<td>770</td>
</tr>
</tbody>
</table>
tumors (18). These observations prompted us to study the status of p53 in adenocarcinomas from Brca2<sup>fl9/fl9</sup> mice. We performed immunohistochemistry using an antibody that recognizes p53 and found that three of four tumors examined failed to show normal staining for p53 protein (Fig. 4B–G). In cells of the adenocarcinoma of mouse 3 (Table 1 and Fig. 4, B and C), strong p53 staining occurred both in the cytoplasm and nucleus. In mouse 4, p53 was expressed in the nuclei (only) of all adenocarcinoma cells (Fig. 4, D and E). In mouse 1, there were no positively stained tumor cells (Fig. 4, F and G), suggesting that this adenocarcinoma had either completely lost p53 expression or that it retained undetectable levels of WT p53. [WT p53 is present in normal cells only at very low levels because of its rapid turnover (29).] The adenocarcinoma of mouse 5 exhibited an apparently normal pattern of p53 staining as p53 was present in the nuclei of only some of the tumor cells (data not shown).

To determine whether the p53 gene was mutated in Brca2<sup>fl9–10/fl9–10</sup>; MMTV-Cre adenocarcinomas, we used PCR to sequence p53 exons 5–9 in either tumor genomic DNA or cDNA synthesized from tumor cell mRNA. Exons 5–9 of p53 encode the sequence-specific DNA binding region, and the majority of mutations in human cancers is located in this region (30). As shown in Table 2, sequencing of multiple clones confirmed that one of four Brca2<sup>fl9–10/fl9–10</sup>; MMTV-Cre adenocarcinomas exhibited a p53 mutation. In tumor case 3, the G to T transversion at nucleotide 888 created a mutation from aspartate to tyrosine at residue 256 in the murine protein. This asparagine residue is conserved in WT human p53, and mutation to tyrosine has been found in human cancers (although it does not qualify as a mutation hot spot according to the online database of p53 mutations available). Interestingly, tumor case 3 displayed an abnormal p53 staining pattern (Fig. 4C), which could have resulted from this mutation. Mutations of p53 have also been identified in lymphomas from mice with Brca2 truncation mutations. Cells from these animals displayed mutations of p53 or other genes encoding proteins involved in cell cycle mitotic checkpoint regulation (31). Taken together, these results suggest that Brca2-mediated tumorigenesis can occur only after certain checkpoints are inactivated.

**Increased Incidence of Mammary Adenocarcinomas in Brca2<sup>fl9–10/fl9–10</sup>; MMTV-Cre; p53<sup>+/−</sup> Mutants Compared with p53<sup>−/−</sup> Mice.** To determine whether down-regulation of p53 promoted tumorigenesis in mammary gland-specific Brca2-deficient mice, we compared the incidence and time of onset of mammary adenocarcinomas in mammary epithelium-specific Brca2-deficient p53<sup>+/−</sup> mice and control p53<sup>−/−</sup> mice. p53<sup>−/−</sup> mice spontaneously developed tumors such as osteosarcomas (the majority), lymphomas, and the occasional mammary adenocarcinoma, consistent with previous studies (24, 32). We performed Southern blotting of tumor cell genomic DNA obtained from five tumors of Brca2<sup>fl9–10/fl9–10</sup>; MMTV-Cre; p53<sup>−/−</sup> or Brca2<sup>fl9–10/fl9–10</sup>; WAP-Cre; p53<sup>−/−</sup> mice. In four of five tumors, in addition to the loss of Brca2 as indicated by the extensive recombination of Brca2<sup>fl9–10</sup> allele, loss of heterozygosity of the p53 locus had also occurred (Fig. 5A). A log-rank test was used to compare the survival curves of the different mutant lines. We detected only a marginal difference between the survival rates of Brca2<sup>fl9–10/fl9–10</sup>; MMTV-Cre; p53<sup>−/−</sup> mutants (median survival of 310 days; n = 9) and Brca2<sup>fl9–10/fl9–10</sup>; MMTV-Cre; p53<sup>−/−</sup> mice (median survival of 470 days; n = 5; P = 0.0128) or p53<sup>−/−</sup> mice (median survival of 385 days; n = 11; P = 0.0113; Fig. 5B). On the other hand, out of 15

<table>
<thead>
<tr>
<th>Tumor case no.</th>
<th>exon 5–9 sequencing</th>
<th>IHC staining</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>No mut.</td>
<td>–</td>
</tr>
<tr>
<td>3</td>
<td>888 G → T</td>
<td>+/+/+(cyt. + nuc.)</td>
</tr>
<tr>
<td>4</td>
<td>No mut.</td>
<td>+(nuc.)</td>
</tr>
<tr>
<td>5</td>
<td>No mut.</td>
<td>+(nuc.)</td>
</tr>
</tbody>
</table>

Microsequencing of p53 exons 5–9 and immunohistochemistry (IHC) with an anti-p53 antibody were performed. No mut., no mutation found. In tumor case no. 3, a nucleotide transversion from G to T was detected at nucleotide position 888 (reference made to p53 cDNA clone GenBank accession no. 581782). This tumor also demonstrated a strong positive staining of p53 in both cytoplasm (cyt.) and nucleus (nuc.) of tumor cells (Fig. 4C). Tumor case no. 1 showed negative (−) staining of p53 (Fig. 4G), case 4 showed positive staining in all tumor cell nuclei (Fig. 4E), and some cells in case no. 5 showed positive staining in their nuclei (data not shown).

**Table 2 p53 status in the four mammary adenocarcinomas from Brca2<sup>fl9–10/fl9–10</sup>; MMTV-Cre mutant mice**
DISCUSSION

The role of the breast cancer susceptibility gene Brca2 in DNA damage repair and Rad51 regulation is now well established. However, until this study, it was unknown whether Brca2 was required for the normal growth of mammary epithelial cells, particularly during pregnancy when extensive proliferation occurs to prepare the mammary gland for lactation. Our analyses indicate that an absence of Brca2 does not impair the expansion of mammary ducts or alveoli during pregnancy. Our data also imply that the potential accumulation of DNA breaks resulting from Brca2 deficiency does not induce a checkpoint for repair or apoptosis. Furthermore, although the mammary epithelium undergoes massive apoptosis during involution, there were no significant differences between mammary-specific Brca2-deficient mice and controls in the kinetics of apoptosis. In contrast, loss of Brca2 in proliferating T lymphocytes increases the level of spontaneous apoptosis (21), possibly through the up-regulation of the p53 target gene Bax (A. M. Y. Cheung and T. W. Mak, unpublished data). The basis for this tissue-specific difference is under investigation.

In agreement with previous studies (17), the loss of Brca2 in mammary glands enhances the development of spontaneous tumors. Inactivation of one WT p53 allele in mice homozygous for a mammary-specific Brca2 mutation significantly skewed the tumor spectrum toward the development of mammary adenocarcinomas. These data complement with the observation of Jonkers et al. (18) that mutations of Brca2 and p53 in myoepithelial cells have synergistic effects on breast cancer development. Although we previously demonstrated that T-cell-specific loss of Brca2 alone does not promote cancerous transformation of these cells, the loss of both Brca2 and p53 in T cells promotes the development of T-cell lymphomas (21). These data, together with the observation of apparently normal mammary tissue development in the absence of Brca2, strongly support the hypothesis that Brca2 functions as a mammary tissue-specific tumor suppressor.

DNA-damaging stress induces most cells to activate molecular checkpoints that induce either cell cycle arrest to allow for repair of the damage or apoptosis to eliminate the cell with genomic aberrations. However, stressed mammary epithelial and ovarian cells ignore these checkpoints and continue to propagate (33), perhaps because these cells are constantly exposed to survival signals from growth-promoting sex hormones that override the apoptotic signals. The unique hormonal milieu of female reproductive tissues may explain why mutations of the BRCA genes specifically promote tumorigenesis in these tissues. The identification of BRCA1’s involvement in X chromosome inactivation also supports the biological importance of BRCA1 in female-restricted tissues (34). In contrast, BRCA2 mutations have been found in some breast cancers in males, suggesting that BRCA2 functions are tissue-specific rather than sex specific.

Certain genetic features are associated with hereditary BRCA breast tumors in humans. Besides being genetically unstable and exhibiting specific chromosomal gains or losses (35), mutations of p53 have been found more frequently in BRCA1- or BRCA2-associated breast tumors than in sporadic breast cancers (28, 36, 37). Moreover, the spectrum of p53 mutations in BRCA-deficient breast tumors is different from that found in sporadic cases (36). In mouse models, novel p53 mutations were found in lymphomas of mice homozygous for Brca2 truncation mutations (31). Our own sequencing and immunohistochemical analyses of p53 mutations in spontaneous mammary adenocarcinomas from Brca2-10/fl9; MMTV-Cre mice showed that the expression patterns of p53 protein were aberrant in these cells are constantly exposed to survival signals from growth-promoting sex hormones that override the apoptotic signals. The unique hormonal milieu of female reproductive tissues may explain why mutations of the BRCA genes specifically promote tumorigenesis in these tissues. The identification of BRCA1’s involvement in X chromosome inactivation also supports the biological importance of BRCA1 in female-restricted tissues (34). In contrast, BRCA2 mutations have been found in some breast cancers in males, suggesting that BRCA2 functions are tissue-specific rather than sex specific.

Certain genetic features are associated with hereditary BRCA breast tumors in humans. Besides being genetically unstable and exhibiting specific chromosomal gains or losses (35), mutations of p53 have been found more frequently in BRCA1- or BRCA2-associated breast tumors than in sporadic breast cancers (28, 36, 37). Moreover, the spectrum of p53 mutations in BRCA-deficient breast tumors is different from that found in sporadic cases (36). In mouse models, novel p53 mutations were found in lymphomas of mice homozygous for Brca2 truncation mutations (31). Our own sequencing and immunohistochemical analyses of p53 mutations in spontaneous mammary adenocarcinomas from Brca2-10/fl9; MMTV-Cre mice showed that the expression patterns of p53 protein were aberrant in three of four tumors.

Structural analyses have shown that the BRC4 region of BRCA2 binds to Rad51 (8) and that the COOH terminus of BRCA2 binds to single-stranded DNA (10). BRCA2 thus works locally with Rad51 in the process of DNA single-strand break (38). However, the mechanism underlying the tissue specificity of BRCA2’s role in tumor suppression remains a mystery. Our study has shown that, unlike the requirement of Brca1 for normal ductal tree expansion during pregnancy (25), Brca2 is not required for normal...
mammary epithelium development. Nevertheless, a proportion of Brca1- and Brca2-deficient animals develop spontaneous mammary tumors after a long latency. It also remains unclear how and why the normal-looking mutant gland progresses toward the cancerous state. If proliferation and the subsequent accumulation of chromosomal aberrations in the mammary epithelium are indeed the forces driving tumorigenic transformation, it will be interesting to study whether the application of DNA-damaging agents or sex hormones such as estrogen and prolactin can accelerate the onset of tumorigenesis in Brca2-deficient animals.

ACKNOWLEDGMENTS

We thank Rama Khokha for help with whole mount analysis; Kelvin So for histology and immunohistochemistry; Ivana Miljanic for DNA sequencing; James Woodgett and Sam Benchimol for critical comments; and Mary Saunders for scientific editing of the manuscript.

REFERENCES

Brca2 Deficiency Does Not Impair Mammary Epithelium Development but Promotes Mammary Adenocarcinoma Formation in $p53^{+/\sim}$ Mutant Mice

Alison M. Y. Cheung, Andrew Elia, Ming-Sound Tsao, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/6/1959

Cited articles
This article cites 38 articles, 7 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/6/1959.full#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/64/6/1959.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/64/6/1959.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.